| Autor: |
Weber WC; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR 97006, USA.; Department of Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, OR 97239, USA., Streblow ZJ; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR 97006, USA., Kreklywich CN; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR 97006, USA., Denton M; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR 97006, USA., Sulgey G; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR 97006, USA., Streblow MM; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR 97006, USA., Marcano D; Ponce Research Institute, Ponce Health Sciences University, Ponce 00716, Puerto Rico., Flores PN; Ponce Research Institute, Ponce Health Sciences University, Ponce 00716, Puerto Rico., Rodriguez-Santiago RM; Ponce Research Institute, Ponce Health Sciences University, Ponce 00716, Puerto Rico., Alvarado LI; Ponce Research Institute, Ponce Health Sciences University, Ponce 00716, Puerto Rico., Rivera-Amill V; Ponce Research Institute, Ponce Health Sciences University, Ponce 00716, Puerto Rico., Messer WB; Department of Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, OR 97239, USA., Hochreiter R; Valneva Austria GmbH, 1030 Vienna, Austria., Kosulin K; Valneva Austria GmbH, 1030 Vienna, Austria., Dubischar K; Valneva Austria GmbH, 1030 Vienna, Austria., Buerger V; Valneva Austria GmbH, 1030 Vienna, Austria., Streblow DN; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR 97006, USA.; Division of Pathobiology and Immunology, Oregon National Primate Research Center, Beaverton, OR 97006, USA. |
| Abstrakt: |
The first vaccine against chikungunya virus (CHIKV) was recently licensed in the U.S., Europe, and Canada (brand IXCHIQ ® , referred to as VLA1553). Other pathogenic alphaviruses co-circulate with CHIKV and major questions remain regarding the potential of IXCHIQ to confer cross-protection for populations that are exposed to them. Here, we characterized the cross-neutralizing antibody (nAb) responses against heterotypic CHIKV and additional arthritogenic alphaviruses in individuals at one month, six months, and one year post-IXCHIQ vaccination. We characterized nAbs against CHIKV strains LR2006, 181/25, and a 2021 isolate from Tocantins, Brazil, as well as O'nyong-nyong virus (ONNV), Mayaro virus (MAYV), and Ross River virus (RRV). IXCHIQ elicited 100% seroconversion to each virus, with the exception of RRV at 83.3% seroconversion of vaccinees, and cross-neutralizing antibody potency decreased with increasing genetic distance from CHIKV. We compared vaccinee responses to cross-nAbs elicited by natural CHIKV infection in individuals living in the endemic setting of Puerto Rico at 8-9 years post-infection. These data suggest that IXCHIQ efficiently and potently elicits cross-nAb breadth that extends to related alphaviruses in a manner similar to natural CHIKV infection, which may have important implications for individuals that are susceptible to alphavirus co-circulation in regions of potential vaccine rollout. |
